Background: The synergy between in vitro and in vivo imaging was investigated in this study.
Patients And Methods: Comparison of fluorodeoxyglucose positron-emission tomography (FDG-PET) and computerised tomography (CT) included 62 patients (group 1), while that for comparison of FDG-PET and serum tumour markers included 26 patients (group 2).
Results: In group 1, FDG-PET had positive and negative predictive values of 81% and 80% respectively, compared to 73.7% and 71.4% for CT, respectively. Combined imaging showed 100% sensitivity and 100% specificity. In group 2, FDG-PET and CEA were both positive in 42.9%, and only CEA was falsely negative in all other cases. FDG-PET and TPA were both positive in 47.6%, and in 52.4% only FDG-PET was positive. NSE and SCC had 100% specificity; their sensitivity was 38% and 25%, respectively.
Conclusion: FDG-PET diagnosis was improved by CT. Because the serum tumour markers were falsely negative in more than 50% and there were no falsely negative results for FDG-PET, combined imaging may allow reduction of cut-off values for conventional serum tumour markers.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Explainable Machine Learning to Predict Treatment Response in Advanced Non-Small Cell Lung Cancer.
JCO Clin Cancer Inform
January 2025
Emory University School of Medicine, Atlanta, GA.
Purpose: Immune checkpoint inhibitors (ICIs) have demonstrated promise in the treatment of various cancers. Single-drug ICI therapy (immuno-oncology [IO] monotherapy) that targets PD-L1 is the standard of care in patients with advanced non-small cell lung cancer (NSCLC) with PD-L1 expression ≥50%. We sought to find out if a machine learning (ML) algorithm can perform better as a predictive biomarker than PD-L1 alone.
View Article and Find Full Text PDFQuantitative expression of estrogen, progesterone and human epidermal growth factor receptor-2 and their correlation with immunohistochemistry in breast cancer at Uganda Cancer Institute.
PLoS One
January 2025
Department of Clinical Support Services, Division of Laboratory and Pathology Medicine, Uganda Cancer Institute, Kampala, Uganda.
The detection of Estrogen Receptor (ER), Progesterone Receptor (PR), and Human epidermal growth factor receptor 2 (HER-2) is important for the stratification of breast cancer and the selection of therapeutic modalities. This study aimed to determine the quantitative expression of ER, PR and HER-2 using Immunohistochemistry and their correlation with quantitative baseline Ct values measured using Quantitative Polymerase Chain Reaction (PCR). This study also assessed the use of fresh breast tissue biopsies preserved in RNAlater solution in the quantitative detection of these receptors using PCR technique.
View Article and Find Full Text PDFPersistent pre-exhausted CD8+ T cells shape the tumor immune microenvironment in anaplastic thyroid cancer.
Endocr Relat Cancer
January 2025
X Zheng, Thyroid and Neck Tumor, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China.
Anaplastic Thyroid Cancer (ATC) is an aggressive form of cancer with poor prognosis, heavily influenced by its tumor immune microenvironment (TIME). Understanding the cellular and gene expression dynamics within the TIME is crucial for developing targeted therapies. This study analyzes the immune microenvironment of ATC and Papillary Thyroid Cancer (PTC) using single-cell RNA sequencing (scRNA-seq).
View Article and Find Full Text PDFPSMA-PET/CT Findings in Patients With High-Risk Biochemically Recurrent Prostate Cancer With No Metastatic Disease by Conventional Imaging.
JAMA Netw Open
January 2025
Ahmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California, Los Angeles.
Importance: The phase 3 randomized EMBARK trial evaluated enzalutamide with or without leuprolide in high-risk nonmetastatic hormone-sensitive prostate cancer. Eligibility relied on conventional imaging, which underdetects metastatic disease compared with prostate-specific membrane antigen-positron emission tomography (PSMA-PET).
Objective: To describe the staging information obtained by PSMA-PET/computed tomography (PSMA-PET/CT) in a patient cohort eligible for the EMBARK trial.
Canine mammary tumors as a promising adjunct preclinical model for human breast cancer research: similarities, opportunities, and challenges.
Arch Pharm Res
January 2025
Laboratory of Biochemistry and Immunology, College of Veterinary Medicine, Chungbuk National University, Cheongju, 28644, Republic of Korea.
Despite significant progress in the field of human breast cancer research and treatment, there is a consistent increase in the incidence rate of 0.5 percent annually, posing challenges in the development of effective novel therapeutic strategies. The failure rate of drugs in clinical trials stands at approximately 95%, primarily attributed to the limitations and lack of reliability of existing preclinical models, such as mice, which do not mimic human tumor biology.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!